|Summary sheet: Methoxphenidine|
|Molecular structure of methoxphenidine|
|Common names||Methoxphenidine, MXP|
|Routes of Administration|
Methoxphenidine (1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine or MXP) is a dissociative hallucinogenic compound of the diarylethylamine chemical class that has been sold online as a designer drug. It induces a state referred to as "dissociative anesthesia" and has similar effects to that of the arylcyclohexylamine and morphinan classes of dissociatives.
This compound was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury. Shortly after the 2013 UK ban on arylcyclohexylamines, methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form. It is often marketed as a replacement for MXE despite many users reporting it as qualitatively different in its effects.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 References
Methoxphenidine, or 2-MeO-Diphenidine is a molecule of the diarylethylamine class. It contains a substituted phenethylamine skeleton with an additional phenyl ring bound to Rα. The terminal amino group of the phenethylamine chain is incorporated into a piperidine ring. Hence, methoxphenidine belongs to the piperidine dissociative class of compounds. Methoxphenidine is structurally analogous to Diphenidine, containing an additional 2-methoxy CH3O- substitution.
MXP acts as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the “k-hole.”
Although it has not been formally studied, the feelings of physical and emotional euphoria which many users report suggests that it may also have action as a dopamine and / or a noradrenaline reuptake inhibitor.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death.
The subjective physical effects of MXP are most similar to that of DXM than any other commonly used dissociative. They can be broken down into several components which progressively intensify proportional to dosage. These are described below and generally include:
- Tactile disconnection - This results in typical states of progressive physical disconnection but is far more consciously controllable than that of other dissociatives. This allows one to choose how much of their body they are currently aware of and connected to simply by directing their focus towards it even throughout higher states of disconnection and out-of-body experiences.
- Pain relief
- Spontaneous physical sensations - The MXP "body high" is a soft, pleasurable vibrating sensation which can be felt all over the body which progressively intensifies throughout the onset before dissipating once the peak has been reached.
- Tactile suppression - This partially to entirely suppresses one's own sense of touch, creating feelings of numbness within the extremities. It is responsible for the anaesthetic properties of this substance.
- Motor control loss - A loss of gross and fine motor control alongside of balance and coordination is prevalent within MXP and becomes especially strong at higher dosages. This means that one should be sitting down before the onset unless they are experienced in case of falling over and injuring oneself.
- Euphoria - This results in feelings of physical euphoria which range between mild pleasure to powerfully all-encompassing bliss.
- Perception of decreased weight - This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate dosages by making the body feel light and effortless to move.
- Dizziness - Although uncommon, some people report dizziness under the influence of MXP.
- Physical autonomy
- Spatial disorientation
- Orgasm suppression
- Visual disconnection - This eventually results in MXP's equivalent of the famous "K-hole" or more specifically, holes, spaces and voids alongside of structures.
- Visual acuity suppression
- Double vision - This component is prevalent at moderate to heavy dosages and makes reading impossible unless one closes an eye.
- Pattern recognition suppression - This effect generally occurs at higher dosages and makes one unable to recognize and interpret perceivable visual data.
- Frame rate suppression
At high dosages, MXP can produce a full range of high level hallucinatory states in a fashion that is less consistent and reproducible than that of many other commonly used psychedelics. These effects include:
- Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) - In comparison to other dissociatives, this effect can occur at heavy dosages, but is considerably less common than the same effect found within psychedelics and deliriants. It feels very dream-like and can be comprehensively described through its variations as delirious in believability, fixed in style, equal in new experiences and memory replays in content, extremely controllable in content and solid in style.
The cognitive effects of MXP are often described as particularly clear-headed in comparison to other dissociatives even at heavy dosages. It is far more controllable, less disorientating and confusing at dosages of equal subjective intensity to that of MXE, DXM and ketamine. The cognitive effects of MXP can be broken down into several separate subcomponents which are listed and described below:
- Dream potentiation
- Consciousness disconnection
- Thought acceleration
- Memory suppression
- Thought deceleration
- Increased music appreciation
- Analysis suppression
- Time distortion - Feelings of time dilation and more time having passed than it actually has are common at moderate to strong dosages.
- Conceptual thinking
- Anxiety suppression
- The afterglow describes the effects that can occur within the 24 hours after the experience itself. Many people report it to be as long-lasting and desirable as the experience itself. It can be described in terms of its physical sensation as one of euphoria, rejuvenation, relaxation and a bodily lightness. In terms of its mental thought processes, it can be described as a significant reduction or loss of anxiety, feelings of contentedness and a highly increased appreciation for music which dissipates a day or so after the experience.
Anecdotal reports which describe the effects of this compound within our experience index include:
Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational MXP use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because MXP has very little history of human usage. Anecdotal evidence from people who have tried MXP within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
As with other NMDA receptor antagonists, the chronic use of MXP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of MXP develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). MXP presents cross-tolerance with all dissociatives, meaning that after the consumption of MXP all dissociatives will have a reduced effect.
Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
- Depressants (1,4-Butanediol, 2M2B, alcohol, benzodiazepines, barbiturates, GHB/GBL, methaqualone, opioids) - This combination potentiates the muscle relaxation, amnesia, sedation, and respiratory depression caused by one another and at higher doses, can lead to a sudden, unexpected loss of consciousness along with dangerously depressed respiration. There is also an increased risk of vomiting while unconsciousness and dying from the resulting suffocation. If nausea or vomiting occurs before consciousness is lost, users should attempt to fall asleep in the recovery position or have a friend move them into it.
- Stimulants - This combination can potentiate the anxiety-inducing, manic, delusional and disinhibiting effects of dissociatives, particularly those without pronounced motor suppressing components such as ketamine. The sum of these effects can increase the likelihood of an anxiety attack, delusions or a psychotic episode.
- Prominent examples include PCP and its analogs 3-MeO-PCP, MXE, and the diarylethylamine dissociatives like diphenidine or ephenidine. There is also evidence that suggests that combining these two increases their neurotoxicity. Anecdotally, worsened comedowns are also commonly reported when these two classes of substances are combined.
- Dissociatives - This combination can unpredictably potentiate the amnesia, sedation, motor control loss and delusions that can be caused by each other. It may also result in a sudden loss of consciousness accompanied by a dangerous degree of respiratory depression. If nausea or vomiting occurs before consciousness is lost, users should attempt to fall asleep in the recovery position or have a friend move them into it.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
- China - As of October 2015 MXP is a controlled substance in China.
- Sweden - MXP is also banned in Sweden.
- Canada - As of March 2016, MT-45 and its analogues, one of which being Methoxphenidine, are Schedule I controlled substances. Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug.
- Italy - MXP is banned in Italy according to the Table of Drugs since 2016. 
- From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24678061
- "Word of mouse": indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/25715070
- 1,2-diarylethylamines for treatment of neurotoxic injury | https://www.google.com/patents/EP0346791B1
- Test purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and differentiation from its meta- and para-substituted isomers | http://onlinelibrary.wiley.com/doi/10.1002/dta.1800/abstract
- MXP Patent | http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=0346791&KC=&FT=E&locale=en_EP
- Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted
- "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" | http://www.sfda.gov.cn/WS01/CL0056/130753.html
- Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara | http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/mars/fler-amnen-foreslas-bli-klassade-som-narkotika-eller-halsofarlig-vara/
- Regulations Amending the Food and Drug Regulations (Parts G and J — Lefetamine, AH-7921, MT-45 and W-18) | http://www.gazette.gc.ca/rp-pr/p2/2016/2016-06-01/html/sor-dors106-eng.php